A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China - Trial NCT06082986
Access comprehensive clinical trial information for NCT06082986 through Pure Global AI's free database. This phase not specified trial is sponsored by Xian-Janssen Pharmaceutical Ltd. and is currently Recruitment Completed. The study focuses on Crohn Disease. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xian-Janssen Pharmaceutical Ltd.
Timeline & Enrollment
N/A
Oct 09, 2023
Dec 15, 2023
Primary Outcome
Percentage of Participants With Endoscopic Remission at Week 24
Summary
Bio-naive participants are defined as the participants who previously have not received any
 biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the
 endoscopic remission at week 24 among bio-naive participants with CD treated with ustekinumab
 in China.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06082986
Non-Device Trial